ANTIBODIES AGAINST SARS-COV-2 S1 SPIKE PROTEIN

摘要

Provided are recombinant monoclonal antibodies that bind to the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2 or COVID-19) spike protein, and methods of use. In various embodiments, the antibodies are fully human antibodies that bind to SARS-CoV-2 spike protein. In some embodiments, the antibodies are useful for inhibiting or neutralizing SARS-CoV-2 activity, thus providing a means of treating or preventing COVID-19 infection in humans. In some embodiments, provided is a combination of one or more antibodies that bind to the SARS-CoV-2 spike protein for use in treating COVID-19 infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the SARS-CoV-2 spike protein. In certain embodiments, the antibodies can be used to make an in vitro diagnostic for detection of COVID-19 in human and non-human animal samples. In still other embodiments, the antibodies can be used to remove virus from patient plasma via plasmapheresis.